Table 1.
Participants’ Characteristics at Baseline .
| Characteristic | Number or median | Percentage or IQR |
|---|---|---|
| Age (year), median (IQR) | 32 | (30–39) |
| Sex, n (% of cohort) | ||
| Male | 13 | 100% |
| Time since HIV diagnosis (months), median (IQR) | 18 | (13-24) |
| Time on cART (months), median (IQR) | 16 | (12-21) |
| cART regimen, n (% of cohort) | ||
| TDF+3TC+EFV | 2 | 15 |
| TDF+3TC+DTG | 9 | 69 |
| TDF+ 3TC+LPV/r | 1 | 7.5 |
| BIC/FTC/TAF | 1 | 7.5 |
| CD4 count at inclusion, n (% of cohort) | ||
| 100 to 199 CD4+/μl | 8 | 62% |
| 200 to 350 CD4+/μl | 2 | 15% |
| >350 CD4+/μl | 3 | 23% |
| Plasma HIV-1 RNA, n (% of cohort) | ||
| <50 copies/mL | 10 | 77% |
| 50-200 copies/mL | 0 | 0% |
| 200-500 copies/mL | 3 | 23 |
TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; EFV, efavirenz; DTG, dolutegravir; LPV/r, lopinavir/ritonavir; BIC/FTC/TAF, bictegravir/emtricitabine/tenofovir alafenamide fumarate.